Form 8-K

8-K — ANAVEX LIFE SCIENCES CORP.

Accession: 0001731122-26-001042

Filed: 2026-08-11

Period: 2026-08-11

CIK: 0001314052

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — e7842_8-k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (e7842_ex99-1.htm)

GRAPHIC (image_001.jpg)

GRAPHIC (image_002.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: e7842_8-k.htm · Sequence: 1

false

0001314052

2026-08-11

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM

8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities

Exchange Act of 1934

Date of Report (Date of earliest event reported): August 11, 2026

ANAVEX

LIFE SCIENCES CORP.

(Exact name of Registrant as Specified in Its Charter)

Nevada

001-37606

98-0608404

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

630 5th Avenue, 20th Floor

New York, NY USA

10111

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 1-844-689-3939

Check the appropriate box below if the Form 8-K filing is intended to simultaneously

satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications

pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant

to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

AVXL

Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company

as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act

of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant

has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant

to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On August 11, 2026, Anavex Life Sciences Corp. (“Anavex” or

the “Company”) issued a press release announcing the filing of the Company’s definitive proxy statement for its 2026

Annual Meeting of Stockholders (the “Press Release”). The Press Release includes an open letter to Anavex’s stockholders

highlighting, among other things, plans to refresh Anavex’s Board of Directors at the 2026 Annual Meeting of Stockholders.

A copy of the Press Release is furnished as Exhibit 99.1 to this Current

Report and is incorporated herein by reference.

The information included in this Item 7.01, including Exhibit 99.1, shall

not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),

or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the

Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated August 11, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the

registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANAVEX LIFE SCIENCES CORP.

Date: August 11, 2026

By:

/s/ Sandra Boenisch

Sandra Boenisch, CPA, CGA

Principal Financial Officer, Treasurer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: e7842_ex99-1.htm · Sequence: 2

EXHIBIT 99.1

Anavex Life Sciences Highlights Highly Qualified

Board and Decisive Actions

to Create Long-Term Value for Stockholders

Files Definitive Proxy Statement and Mails Letter

to Stockholders

Urges Stockholders to Vote “FOR” All

Six Anavex Director Nominees on the WHITE Proxy Card

Underscores PVG’s Lack of Clear Plan and Inexperienced

Slate of Director Nominees

NEW YORK, NY, August 11, 2026 – Anavex Life Sciences Corp. (“Anavex”

or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for

central nervous system (“CNS”) diseases with high unmet medical needs, today announced that it has filed definitive proxy

materials with the Securities and Exchange Commission (“SEC”) in connection with its upcoming 2026 Annual Meeting of Stockholders

(the “2026 Annual Meeting”) scheduled to be held on September 24, 2026. Stockholders of record as of July 31, 2026 will be

entitled to vote at the meeting. Anavex’s definitive proxy materials can be accessed for free by visiting EDGAR on the SEC website

at www.SEC.gov.

In conjunction with the definitive proxy statement filing, the current

Anavex Board members standing for reelection at the 2026 Annual Meeting are mailing a letter to the Company’s stockholders. Key

takeaways from the letter include:

● Executing

a Clear Strategy to Enhance Long-Term Stockholder Value: Following a significant leadership

transition, the Board has taken decisive action to stabilize the company and create value

for stockholders. The Special Committee of the Board moved quickly to appoint Dr. Terrie

Kellmeyer as interim CEO to help support the Company’s next phase of execution. Anavex

is moving ahead with oral blarcamesine (ANAVEX®2-73) across three CNS indications while

prioritizing FDA engagement to establish a clear, data-driven regulatory path forward.

● Advancing

Board Refreshment with Two Highly Qualified, Independent Director Candidates: Following

a thorough search process, the Executive Committee of the Board nominated Mr. Gautam Patel

and Dr. Adrian Senderowicz, two highly qualified, independent candidates who will bring directly

relevant life sciences, capital markets and drug development expertise to the Board and are

expected to immediately contribute to the Company’s strategy and help create value

across the business. If Anavex’s recommended nominees are elected at the 2026 Annual

Meeting, half of the Board will have been refreshed since the beginning of 2026, and all

Board members will be independent.

● PVG

is Attempting to Take Control with No Clear Plan: PVG’s own proxy statement offers

no discussion of any plan or strategy for the Company. Stockholders should carefully consider

whether PVG has made the case that its nominees can effectively guide Anavex through a critical

regulatory and development period.

● PVG’s Nominees Lack Critical Drug Development and Regulatory Expertise: Based on the Company’s review, PVG’s

slate is concentrated almost entirely in investment management and equity research, with limited demonstrated experience actually governing

or operating a public company. Only one of six nominees has a clinical medical background, and none have direct experience in FDA regulatory

affairs or pharmaceutical drug development, presenting a meaningful gap for a board overseeing a clinical-stage biopharmaceutical company.

The full text of the letter being mailed to stockholders follows:

Dear Anavex Stockholder,

The future direction of the Company is in your hands. Patrick

Adams, through his fund PVG Asset Management Corporation (“PVG”), is attempting to take control of the Anavex Board of Directors

at the Company’s Annual Meeting of Stockholders on September 24, 2026. If successful, Mr. Adams will gain effective control of the

Company without paying you a premium for your investment and despite only owning 0.35% of the Company’s outstanding shares of common

stock.[1]

We urge you to vote “FOR” Anavex’s six

highly qualified, independent director nominees on the WHITE universal proxy card today for the following three reasons:

Reason #1: Anavex’s current Board members standing for

election have taken decisive action to position the Company for long-term value creation

Your current Board members standing for election at the 2026

Annual Meeting have taken decisive action to stabilize the Company and create long-term value for stockholders.

Soon after the termination of our former CEO in April 2026, we

appointed Dr. Terrie Kellmeyer, the Company’s former Senior Vice President of Clinical Development and a Senior Advisor to Anavex,

as interim CEO. Dr. Kellmeyer has spent her entire career in drug development, building and leading clinical and regulatory functions

across the full lifecycle of drug development, and we are confident she is the right person to lead the Company during this period of

transition. We also conducted a thorough search supported by an independent search firm and identified Mr. Gautam Patel and Dr. Adrian

Senderowicz – two highly qualified, independent director candidates who bring life sciences, capital markets, and drug development

expertise to the Board.

We are urgently moving ahead with our lead candidate, oral blarcamesine

(ANAVEX®2-73), across three CNS indications – early Alzheimer’s disease, Rett syndrome, and Fragile X syndrome –

and are prioritizing FDA engagement to establish a clear, data-driven regulatory path forward.

The Board, alongside Dr. Kellmeyer and the rest of the management

team, has laid out a plan to advance its programs that have the greatest potential for success:

[1] Ownership data as of

July 31, 2026

● Alzheimer’s Disease Program: In March 2026, the Company opened an investigational new drug application (IND) for early

Alzheimer’s disease with the FDA, a key step enabling U.S. clinical studies and substantive FDA discussions on the path forward.

Two foundational clinical pharmacology studies are now underway under this IND: an absorption, distribution, metabolism and excretion

(ADME) study expected to begin in the third calendar quarter of 2026, and a drug-drug interaction (DDI) study where dosing has already

started. Both studies are designed to strengthen the regulatory pathway across all blarcamesine indications in parallel with our ongoing

early Alzheimer’s disease program. We intend to engage with the FDA on a U.S. clinical development strategy, informed in part by

our review of the EMA’s CHMP assessment report. Additionally, we reinforced our commitment to the Alzheimer’s community through

our participation in the AAIC conference in London this July.

● Rett Syndrome Program: Blarcamesine already holds Orphan Drug, Rare Pediatric Disease, and Fast Track designations from the

FDA for Rett syndrome, and we have aligned with the FDA on a Phase 3 trial protocol for adult patients, a critical step toward a registrational

path. We intend to discuss expanding the protocol to include pediatric patients, with more details to come as that conversation progresses.

● Fragile X Syndrome Program: Blarcamesine has received Orphan Drug Designation from the FDA for Fragile X syndrome, and building

on that designation, we plan to open discussions with the FDA on a clinical development strategy for the program, with further details

to follow as it advances.

As it relates to our Nasdaq listing, on May 20, 2026, Anavex

received a delinquency notification from Nasdaq for failing to timely file its Quarterly Report on Form 10-Q for the quarter ended March

31, 2026. The notice did not affect the Company’s listing, and we are in compliance with all other requirements for the continued

listing of our common stock on The Nasdaq Global Select Market. We have submitted a compliance plan to Nasdaq and released preliminary

second fiscal quarter financial results and a business update to keep stockholders informed. We are working diligently to complete our

outstanding periodic filings and fully regain compliance as quickly as possible.

Reason #2: Anavex’s recommended nominees have the right

skills, qualifications, and expertise and, if elected, half of the Board will have been refreshed in just seven months

Your current Board members standing for election are entirely

independent and will continue to bring critical institutional knowledge that we believe will advance the right path forward. Following

a thorough search process, we are also nominating two new, independent candidates, Mr. Gautam Patel and Dr. Adrian Senderowicz, who will

bring significant, relevant life sciences experience and complementary skills to the Board that are expected to immediately contribute

to the Company’s strategy and help create value across the business. Upon election, half of the Anavex Board will have been refreshed

since the beginning of 2026, and all of the Board members will be independent.

To ensure our continued progress without disruption, Anavex

is seeking your vote on the WHITE proxy card “FOR” the Company’s six director nominees, comprising four

current independent directors and two newly nominated independent candidates:

√ Dr.

Jiong Ma (Independent Chair): Partner at Phoenix Venture Partners and experienced

operator with 30+ years of experience investing in, building and scaling technology and life

sciences companies globally.

√ Dr.

Peter Donhauser: Physician and clinical research leader with 20+ years of experience

in integrated medical care, clinical trial oversight and private practice leadership.

√ Dr.

Axel Paeger: CEO of AMEOS Group, a leading European healthcare provider, with 30+ years

of clinical, operational and executive leadership experience.

√ Mr.

Gautam Patel (new independent nominee): Managing Director at Tarsadia Investments

with 30+ years of corporate finance, investment management and board leadership experience

across life sciences, financial services and technology.

√ Dr.

Adrian Senderowicz (new independent nominee): Former Chief Medical Officer at

public and private clinical-stage companies with 30+ years of clinical and regulatory leadership

experience across the life sciences industry.

√ Dr.

Claus van der Velden: CFO and Managing Director of NetCologne GmbH, a regional telecommunications

provider in Germany, bringing 20+ years of experience leading public company finance,

governance and enterprise oversight functions.

Reason #3: Patrick Adams is seeking effective control of Anavex

without disclosing any strategy to create value and without paying you a premium for that control

We believe electing any of the PVG nominees would introduce unnecessary

risk and disruption at a critical moment for the Company, its pipeline and its stockholders. PVG’s own proxy statement offers no

discussion of any plan or strategy for the Company, and it discloses only very limited information about PVG, Mr. Adams, and their nominees

– including their backgrounds, ownership, and any arrangements tied to the solicitation. PVG and Mr. Adams together own just 0.35%

of Anavex’s outstanding shares yet are seeking effective control of your Board without paying stockholders any premium, asking you

to trust an unproven slate with no stated direction for the Company.

Beyond the absence of any stated strategy, PVG’s own nominee

disclosures raise serious questions about whether any of their nominees would provide the right skills, qualifications, or expertise necessary

to contribute to your Board. PVG’s slate is concentrated almost entirely in investment management and equity research, with limited

demonstrated experience actually governing or operating a public company. Only one of the six nominees has a clinical medical background,

and none have direct experience in FDA regulatory affairs or pharmaceutical drug development, presenting a meaningful and concerning gap

for a board tasked with overseeing a clinical-stage biopharmaceutical company through FDA engagement and a critical regulatory period.

Reject PVG’s Brazen Attempt to Acquire Control of the

Company Without Paying You a Premium; Vote “FOR” Anavex’s Six Highly Qualified Director Nominees on the WHITE Proxy

Card Today

Your Board nominees have spent the past several months overseeing

a disciplined, data-driven clinical strategy while taking decisive action to refresh its membership and leadership, bringing in highly

qualified new independent directors and installing experienced interim leadership through a critical transition. PVG, by contrast, has

not offered stockholders any strategy of its own, and its nominees have limited public company governance experience and no meaningful

FDA regulatory or drug development background. At a moment when this Company needs steady, qualified oversight to advance its CNS pipeline,

your current Board has demonstrated exactly that, while PVG has not made the case that its nominees can do the same. We urge you to

vote FOR all six of Anavex’s nominees on the enclosed WHITE proxy card.

If you have any questions or require any assistance with voting

your shares, please call:

Innisfree M&A Incorporated

500 Fifth Avenue, 21st Floor

New York, NY 10110

Stockholders may call toll-free at (877)

750-0831

Brokers, banks and other nominees may call

collect at (212) 750-5833

We look forward to engaging with investors as we move toward

the Annual Meeting and are unwavering in our commitment to act in the best interests of the Company and all stockholders.

Sincerely,

Dr. Jiong Ma

Independent Chair

Dr. Peter Donhauser

Independent Director

Dr. Axel Paeger

Independent Director

Dr. Claus van der Velden

Independent Director

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical

company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric

disorders. Further information is available at www.anavex.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning

of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements regarding the

Company’s plans, strategies and expectations regarding the 2026 Annual Meeting, director nominations, the proxy solicitation, the

Company’s go-forward strategy, clinical development programs, business prospects, and potential actions of the Board and the Executive

Committee, are forward-looking statements. These statements can be identified by the use of forward-looking terminology, including the

words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,”

“may,” “will,” “would,” “could” and similar expressions, or the negative thereof. Many

factors may cause actual results to differ materially from those projected in any of such forward-looking statements, including the risks

and uncertainties set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, and subsequent

filings and furnishings with the SEC, which should be considered together with any forward-looking statement. Readers are cautioned not

to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are

qualified in their entirety by this cautionary statement, and Anavex Life Sciences Corp. undertakes no obligation to revise or update

this press release to reflect events or circumstances after the date hereof except as required by law.

Important Additional Information and Where to Find It

The Company has filed a definitive proxy

statement on Schedule 14A, an accompanying WHITE proxy card, and other relevant documents with the SEC in connection with the

solicitation of proxies from the Company’s stockholders for the 2026 Annual Meeting. THE COMPANY’S STOCKHOLDERS ARE

STRONGLY ENCOURAGED TO READ THE COMPANY’S DEFINITIVE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), THE

ACCOMPANYING WHITE PROXY CARD AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN IMPORTANT

INFORMATION. Stockholders are able to obtain the definitive proxy statement, any amendments or supplements to the proxy statement

and other documents that the Company files with the SEC at no charge at the SEC’s website at www.sec.gov. Copies are also

available at no charge at the Company’s website at www.anavex.com.

Certain Information Regarding Participants

The Company, its directors and certain of its executive officers may be

deemed to be “participants” (as defined in Schedule 14A under the Securities Exchange Act of 1934, as amended) in the solicitation

of proxies from the Company’s stockholders in connection with the matters to be considered at the 2026 Annual Meeting. Information

regarding the names of the Company’s directors and executive officers and certain other individuals and their direct or indirect

interests in the Company, by security holdings or otherwise, is set forth in the sections entitled “Compensation of Directors,”

“Executive Compensation,” and “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder

Matters” of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025 (available here), and any

subsequent filings on Forms 3, 4 and 5 filed with the SEC. Additional information regarding the identity of potential participants, and

their direct or indirect interests, by security holdings or otherwise, are set forth in the Company’s definitive proxy statement

for the 2026 Annual Meeting which has been filed with the SEC. These documents are available free of charge at the SEC’s website

at www.sec.gov.

Investor

Relations:

SCR Partners, LLC

Alex Arzeno

Tel: 203-550-3972

Email: alex@scr-ir.com

Tripp

Sullivan

Tel: 615-942-7077

Email: tsullivan@scr-ir.com

For Media:

Collected Strategies

Nick Lamplough / Dylan O’Keefe

AVXL-CS@collectedstrategies.com

GRAPHIC

Filename: image_001.jpg · Sequence: 3

Binary file (3103 bytes)

Download image_001.jpg

GRAPHIC

Filename: image_002.jpg · Sequence: 4

Binary file (2479 bytes)

Download image_002.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Aug. 11, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 11, 2026

Entity File Number

001-37606

Entity Registrant Name

ANAVEX

LIFE SCIENCES CORP.

Entity Central Index Key

0001314052

Entity Tax Identification Number

98-0608404

Entity Incorporation, State or Country Code

Entity Address, Address Line One

630 5th Avenue

Entity Address, Address Line Two

20th Floor

Entity Address, City or Town

New York

Entity Address, State or Province

Entity Address, Postal Zip Code

10111

City Area Code

844

Local Phone Number

689-3939

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value $0.001 per share

Trading Symbol

AVXL

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration